How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,660 results for

Hypertension Evaluation History

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

32041. MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation

the Mirena IUD or who have had an endometrial ablation and who still have one or both ovaries, with FSH level greater than 20 mIU/mL and estradiol less than or equal to 50 pg/mL. Having bothersome hot flashes and/or night sweats. In general good health as determined by medical history, blood pressure, and heart rate: Absence of uncontrolled hypertension greater than 160/100; Resting heart rate less than 110 beats per minute;. No history of myocardial infarction, angina, or cerebrovascular events (...) ;. No history of liver, renal disease, or uncontrolled seizure disorder. Absence of uncontrolled metabolic disease (such as diabetes) and absence of current infectious disease (such as acute symptoms of mononucleosis) that would put staff and other participants at risk. Signed informed consent. Exclusion Criteria: Use of hormone therapy or hormonal contraceptives (with the exception of the Mirena IUD) during the 2 months before enrollment. Vaginal postmenopausal estrogens allowed, with the exception

2010 Clinical Trials

32042. Transcutaneous Non-invasive Stimulation of the Vagus Nerve for the Treatment of Difficult-to-treat Epilepsy

Volunteers: No Criteria Inclusion Criteria: Written Informed Consent Patients of both gender, aged from 18-75 years Diagnosis of epilepsy according to the diagnosis criteria of the DSM IV/ ICD 10 (especially G 40.1 /G 40.2/ G 40.3) Insufficient response to at least one attempt of treatment in medical history with anticonvulsive medication, dosed sufficiently long and high Antiepileptic Drugs (AED) therapy must be stable at a level that promises long-term continuity for at least 10 before study start (...) brain injury in medical history including invasive and non-invasive methods of therapy (tumor surgery, "Gamma Knife Surgery") Indications of structural impairment of the basal ganglia or the brain stem active implants (e.g. cochlea implants, VNS, pacemaker) Severe neurological diseases (e.g. Morbus Parkinson, systemic neurologic diseases severe internistic diseases (e.g. arterial hypertension, respiratory failure) Bronchial asthma malignant diseases of any kind, within five years before study start

2010 Clinical Trials

32043. An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults

to approved thienopyridines. Exhibit any signs or symptoms of an infection. Have a hematocrit <18%. Exhibit any history of bleeding diathesis, bleeding requiring in-hospital treatment, or papillary necrosis. Have active internal bleeding. Have a history of spontaneous bleeding requiring in-hospital treatment. Have gross hematuria or >300 red blood cells (RBC)/high-powered field (HPF) on urinalysis at the time of screening. History of previous intraocular hemorrhage which required treatment with surgery (...) , whereas a high PRI reflects weak/absent inhibition of P2Y12. Change From Baseline in the Area Under the Aggregation Curve at Day 12 [ Time Frame: Baseline, Day 12 ] AUC to 20 micromolar (μM) adenosine diphosphate (ADP), 6.5μM ADP, Collagen, and thrombin receptor activator for peptide 6 (TRAP-6) were calculated by whole blood multi-electrode aggregometry (MEA) assay. Platelet aggregation was continuously recorded for 5 minutes and quantified as area under the aggregation curve, measured in aggregation

2010 Clinical Trials

32044. The Effectiveness of Personalized Stroke Risk Communication

works better for veterans. The investigators also want to assess the impact of personalized stroke risk communication to patients at risk for stroke on patient knowledge, beliefs, and preferences for risk reduction behaviors and evaluate the impact of personalized risk communication on medication adherence and blood pressure. The investigators plan to enroll approximately 100 veterans for this study. All veterans will be from the Durham VA Primary Care Clinics. The investigators will ask everyone (...) with hypertension do not adequately translate their risk factors into an accurate estimation of stroke risk. Improving the accuracy of stroke risk perceptions may be particularly important in motivating risk reduction in patients. Objectives: The objectives of this study are to: 1.) Assess the impact of personalized stroke risk communication to patients at risk for stroke on patient knowledge, beliefs, and preferences for risk reduction behaviors. 2.) Evaluate the impact of personalized risk communication

2010 Clinical Trials

32045. A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

entry Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before trial entry Nasopharyngeal carcinoma Active infection (infection requiring IV antibiotics), including active tuberculosis, or known and declared human immunodeficiency virus (HIV) Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, cardiac failure or liver failure Uncontrolled hypertension defined as systolic blood pressure >=180 millimeter of mercury (mmHg (...) ) and/or diastolic blood pressure >=130 mmHg under resting conditions Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin [beta-HCG] test) or breastfeeding Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy Other concomitant anticancer therapies Documented or symptomatic brain or leptomeningeal metastasis Clinically relevant coronary artery disease or history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia

2010 Clinical Trials

32046. A Bioequivalence (BE) Study in Healthy Subjects

(QTc) interval >450 milliseconds (msec). Subjects with a current or past history of clinically significant elevated blood pressure (Supine systolic blood pressure greater than or equal to 140 millimeters of mercury [mmHg] or Supine diastolic blood pressure greater than or equal to 90 mmHg) Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, or metabolism (...) infection. Have a positive result for syphilis test, or show evidence of possible infection. Use or intend to use over-the-counter or prescription medication 7 and 14 days, respectively prior to dosing. Blood donation of more than 200 mL of blood and component blood donation within one month prior to dosing, or those who have donated more than 400 mL of blood within 3 month prior to dosing, or history of blood donation of more than 950 mL within the last 12 months. Have an average weekly alcohol intake

2010 Clinical Trials

32047. Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

-label group are descriptive. Change From Baseline to Week 24 in Systolic and Diastolic Blood Pressure (SBP and DBP) [ Time Frame: Baseline and week 24 ] The term "baseline" refers to the last observation before the start of randomised trial treatment (or of open-label treatment for the open-label arm). In this endpoint, the "measured values" show unadjusted values, whereas the statistical analyses show adjusted values. Statistics for open-label group are descriptive. For blood pressure, data (...) ); Signed and dated written informed consent by date of Visit 1 Exclusion criteria: Uncontrolled hyperglycaemia; Acute coronary syndrome (non-STEMI, STEMI and unstable angina pectoris), stroke or TIA within 3 months prior to informed consent; Indication of liver disease, either ALT, AST, or alkaline phosphatase above 3 x ULN; Impaired renal function (eGFR<50 ml/min); Bariatric surgery within the past two years or other GI surgeries; Medical history of cancer; Contraindications to sitagliptin; Blood

2010 Clinical Trials

32048. High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

: Giving high doses of chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor bone marrow transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against (...) High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study

2010 Clinical Trials

32049. Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules

: 18 Years to 55 Years (Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Healthy male and/or female literate subjects (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). Body Mass Index (BMI) of 17.5 to 26.4 kg/m2; and a total body weight >50 kg (110 lbs). Exclusion Criteria (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Bioavailability Study Comparing 10 mg Amlodipine Besylate Orally Disintegrating Tablets (ODT) And 10 mg Amlodipine Besylate Capsules The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01177293

2010 Clinical Trials

32050. Elevated Circulating FFA and Intrahepatic Lipid Content

sex Fasting plasma glucose >6.1 mmol/l Haemoglobin <7.8 mmol/l Engagement in programmed exercise > 2 hours total per week Elevated liver enzymes: ALAT > 45 U/L, ASAT > 35 U/L, ALP> 140 U/L, Gamma-GT > 70 U/L Hypertension: blood pressure > 140 mmHg systolic or 90 mmHg diastolic First degree relatives with history of liver disease and diabetes mellitus Any medical condition requiring treatment and/or medication use Alcohol consumption of more than 20 g per day (± 2 units) Unstable body weight (...) may be an underlying factor for hepatic lipid accumulation. Human studies using hepatic 1H-MRS reported that intrahepatic lipid (IHL) content is associated with obesity, the metabolic syndrome and diabetes. Furthermore, a period of 36 hours of fasting increased IHL dramatically. These conditions are characterized by elevated plasma FFA levels. We hypothesize that an increased passive uptake of FFAs can lead to a mismatch between uptake and oxidation when FFA availability is high. Interestingly

2010 Clinical Trials

32051. Inuniv and Working Memory

for MeSH terms Attention Deficit Disorder with Hyperactivity Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Guanfacine Antihypertensive Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs (...) of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01177306 Recruitment Status : Completed First Posted : August 9, 2010 Last Update Posted : July 28, 2014 Sponsor: Lori A. Schweickert, MD Collaborator: Shire Information provided by (Responsible Party): Lori A. Schweickert, MD, Schweickert, Lori A., M.D. Study Details Study Description Go to Brief Summary: Minimum 24 subjects

2010 Clinical Trials

32052. Tinnitus Retraining Therapy Trial

of abnormal vasculature or high blood pressure contributing to the tinnitus Feigning tinnitus or hearing loss Evidence by audiological testing of a treatable etiology of the tinnitus, such as conductive hearing impairment as shown by pure-tone thresholds, abnormal acoustic immittance, abnormal stapedial reflex test, or abnormal auditory brainstem response Predisposing disease with tinnitus symptoms amenable to medical or surgical intervention, including but not limited to; chronic otitis media (...) is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01177137 Recruitment Status : Completed First Posted : August 6, 2010 Results First Posted : November 21, 2018 Last Update Posted : November 21, 2018 Sponsor: Johns Hopkins Bloomberg School of Public Health Collaborators: National Institute on Deafness and Other Communication Disorders (NIDCD) University of Alabama

2010 Clinical Trials

32053. Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01177007 Recruitment Status : Completed First Posted : August 6, 2010 Results First Posted : August 28, 2017 Last Update Posted : August 28, 2017 Sponsor: Yale University Information (...) infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe. Outcome Measures Go to Primary Outcome Measures : Time to Progression (TTP) of the Treated Lesion(s) According to RECIST Criteria [ Time Frame: Evaluated 4 weeks following each TheraSpheres procedure, and at 2-3 month intervals thereafter. ] This outcome was not assessed. Instead, the primary outcome

2010 Clinical Trials

32054. Probiotics and Endotoxemia

Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Body mass index ≥ 27 kg/m2; above 18 years of age Used to eat high fat diet (more than 40% of total energy intake) Exclusion Criteria: Treated cardiovascular risk factors, treated hypertension, treated dyslipidemia, treated diabetes; Known diabetes, hypertension, dyslipidemia Severe illnesses Artificial heart valve Immunosuppression Regular consumption of probiotics History of bariatric surgery Consumption or wish to consume Orlistat (...) the HOMA-IR index calculated as the product of fasting plasma insulin (in microunits per milliliter) and fasting plasma glucose (in millimoles per liter), divided by 22.5. Higher HOMA values indicate higher IR. Glycated haemoglobin is used as a biological measure indicator of blood glucose concentration over 3 months. Brachial blood pressure of the volunteers before and after the 12 week intervention. [ Time Frame: 12 weeks ] Blood lipids in the volunteers before and after the 12 week intervention

2010 Clinical Trials

32055. Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction

before adding more. Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction (REMINDER) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01176968 Recruitment Status : Completed First Posted : August 6, 2010 Results First Posted : August 15, 2016 Last Update Posted : August (...) (Clinical Trial) Actual Enrollment : 1012 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention Official Title: A Double-blind, Randomized, Placebo-controlled Trial Evaluating The Safety And Efficacy Of Early Treatment With Eplerenone In Patients With Acute Myocardial Infarction Study Start Date : September 2010 Actual Primary Completion Date : October 2012 Actual Study

2010 Clinical Trials

32056. Esmolol Infusion During Laminectomy: Effect on Quality of Recovery

-Sinai Medical Center Information provided by (Responsible Party): Roya Yumul, M.D.,PhD., Cedars-Sinai Medical Center Study Details Study Description Go to Brief Summary: The purpose of this study is to evaluate the effects of esmolol, a drug which is commonly administered during surgery to help control blood pressure and heart rate, on postoperative pain levels and requirements for pain medication. Condition or disease Intervention/treatment Phase Laminectomy Drug: Esmolol Drug: Saline Phase 4 (...) Laminectomy: Effect on Quality of Recovery The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01179113 Recruitment Status : Terminated (The preliminary result didn't show any benefit.) First Posted : August 11, 2010 Results First Posted : August 30, 2016 Last Update Posted : November 2, 2016 Sponsor: Cedars

2010 Clinical Trials

32057. Treatment Resistant Depression (Pilot)

, blood pressure, pulse-oximetry, and an electrocardiogram strip will be routinely monitored. Serial labs and clinical/safety ratings will be done pre-, during, and post-infusion, with the last assessments being used to assure that subjects have returned to their "baseline" prior to discharge from the research unit. Participants will continue to see their primary psychiatrist throughout the study. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial (...) ; not currently psychotic and no history of psychosis within the previous 12 months; psychosis reported in the distant past may not be exclusionary if brief, per PI's judgment; no history of significant clinical or intolerable side effects or complications from clonidine; if a female of child-bearing potential: not pregnant or breast feeding and agrees to use birth control during the time of pre-dosing and infusions; and able to give informed consent. Exclusion Criteria: confirmed bipolar disorder

2010 Clinical Trials

32058. Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin

not be seeking treatment for methamphetamine abuse/dependence. Exclusion Criteria: Ill health (major cardiovascular, renal, endocrine, hepatic disorder, to be determined by history provided by the prospective subject or laboratory evaluation as outlined below). Current diagnosis of other drug or alcohol physical dependence (other than nicotine or caffeine). History of major organic psychiatric disorder (psychosis, schizophrenia, bipolar, mania) or significant psychiatric symptoms at the time of evaluation (...) session, each subject received prazosin (1 or 2 mg) or prazosin placebo. The heart rate was measured. Then, one hour later, methamphetamine placebo or methamphetamine (20mg) was given and the heart rate was measured again. Blood Pressure Effects of Prazosin on Methamphetamine [ Time Frame: 0 hr time point after prazosin and 1 hr time point after methamphetamine ] Blood pressure effects of prazosin on methamphetamine; In each session, each subject received prazosin (1 or 2 mg) or prazosin placebo

2010 Clinical Trials

32059. Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)

: Virginia Commonwealth University Collaborator: Exalenz Bioscience LTD. Information provided by (Responsible Party): Virginia Commonwealth University Study Details Study Description Go to Brief Summary: The purpose of the study is to demonstrate that the ¹³C-Octanoate Breath Test (OBT) can be used as an aid, in conjunction with other clinical information and medical history, for evaluating disease severity and detecting NASH with a high probability. Condition or disease Intervention/treatment Phase (...) cm for women triglycerides > 150 mg/dl fasting blood sugar > 110 mg/dl HDL cholesterol < 40 mg/dl blood pressure > 130/85 mm Hg No other known co-existent liver disease, excluded by appropriate serologic testing Exclusion Criteria: Positive studies for any of the following: hepatitis C (PCR) hepatitis B (surface antigen or DNA) iron saturation > 60% + gene test for hereditary hemochromatosis antinuclear antibody at a titer > 1: 160 along with hypergammaglobulinemia and ALT levels>250 U/L Patient

2010 Clinical Trials

32060. Study of FP-1039 in Subjects With Endometrial Cancers

Note: Subjects with CNS metastases who have completed a course of radiotherapy and who have been on a stable dose of glucocorticoids for at least 4 weeks are eligible. Uncontrolled intercurrent illness including but not limited to an active infection, hypertension, psychiatric, or substance abuse disorders that would preclude consent, limit compliance with study requirements, or confound safety interpretation. Unable or unwilling to abide by the study protocol or cooperate fully (...) Cancers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01244438 Recruitment Status : Withdrawn (Study FP1039-002 was not feasible. The original assumption was at least 5% of patients screened would qualify, but after screening 70 patients, none qualified.) First Posted : November 19, 2010 Last Update

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>